GN-RESOUND
ReSound today announced the global launch of the ReSound Enya family of hearing aids, making the company’s industry-leading, innovative hearing technologies accessible to even more people living with hearing loss. For the first time, the company is making its renowned sound expertise and innovative wireless technologies, which were previously reserved to the highest price points, available in lower priced solutions.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150930006212/en/
ReSound Enya delivers excellent sound quality in discreet, durable models designed to meet the challenges of a rich, active lifestyle. With ReSound Enya, users have access to the category’s best available performance without sacrificing comfort and ease of use.
ReSound is the first in the industry to build advanced connectivity into an affordable device, allowing wearers to:
- Enjoy clear speech and a comfortable listening experience in everyday situations both indoors and out.
- Stream sound from the TV, mobile phone, music player directly to the ReSound Enya hearing aids with ReSound Unite™ wireless accessories.
- Use a smartphone to easily control the hearing aid volume and program settings with the ReSound Control™ app, paired with the ReSound Unite Phone Clip+.
- Get relief from tinnitus with the in-built Tinnitus Sound Generator™.
ReSound also recently introduced ReSound ENZO2 ™, the world’s most advanced Smart Hearing aid for people with severe-to-profound hearing loss. ReSound ENZO2 builds on the revolutionary capabilities of ReSound LiNX2 ™, the world’s first full family of Made for iPhone hearing aids. Wearers will experience a vivid sense of space and speech with Spatial Sense™, and have access to direct streaming of sounds to their hearing aids, including music and phone calls. ReSound ENZO2 is easily controlled by the ReSound Smart™ app, providing discreet, on-the-go personalization directly from a user’s smartphone, or from their wrist using the app extension for Apple Watch. ReSound ENZO2 is available to U.S. consumers immediately and coming soon to additional markets around the world.
“We are pleased to be able to offer even more choices for people looking to take control of their hearing loss,” said GN ReSound CEO Anders Hedegaard. “Our dedication to delivering the most advanced hearing solutions also means making these technologies accessible to as many users as possible. Diversifying our portfolio ensures that whether a person is living with mild or severe-to-profound hearing loss, they will be able to find a superior hearing solution that meets their unique needs at the price point that fits their lifestyle. We remain committed to pushing the limits in terms of what is possible for Smart Hearing solutions, and we are proud to offer a complete portfolio of innovative options that truly improve peoples’ lives.”
The ReSound Control app is available for free and compatible with iOS and Android devices. Consumers can find more information about ReSound Enya at www.resound.com/enya . For U.S. consumers and individuals interested in information about ReSound Smart Hearing solutions, including ReSound ENZO2 and the ReSound Smart app, please visit www.resound.com .
About GN ReSound
GN ReSound is a leading international developer and manufacturer of advanced and innovative hearing healthcare solutions. It advances the wireless revolution with its unique 2.4 GHz and Bluetooth® Smart solutions. GN ReSound has reinvented the hearing system with its revolutionary ReSound LiNX2 hearing aids, and is driving and defining the future of hearing care. The company demonstrates its commitment to making life sound better through its research, insights and expertise in sound.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150930006212/en/
Contact:
GN ReSound
John Procter, +1-703-587-9967
jprocter@mcbeestrategic.com
or
Jessica
Larkin,+1-202-997-5582
jlarkin@mcbeestrategic.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release
Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi
DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 20:23:00 CEST | Press release
DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational HighlightsRevenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit marg
Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 20:18:00 CEST | Press release
The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-clas
Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 20:00:00 CEST | Press release
Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum